tDCS plus speech and language therapy (SLT) versus sham tDCS plus SLT for improving aphasia: dropouts Dropouts and adverse events · patients with improving aphasia in patients with aphasia after stroke
1 finding from 1 review
Health‐related quality of life (HRQoL) · women with early breast cancer
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Low
Rate of decline of serum bilirubin (micromol/L/hr) · neonatal jaundice
1 finding from 1 review
Bilirubin‐induced brain dysfunction (defined as either the pathological finding of deep‐yellow staining of neurons and neuronal necrosis of the basal ganglia and brainstem nuclei or acute or chronic neurological deficit including athetoid cerebral... · neonatal jaundice
1 finding from 1 review
Mortality (all cause) · neonatal jaundice
1 finding from 1 review
Cognitive function · people with cerebral small vessel disease and no dementia
1 finding from 1 review
Incidence of dementia · people with cerebral small vessel disease and no dementia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major bleeding (intracranial and extracranial) · people with cerebral small vessel disease and no dementia
1 finding from 1 review
Functional ability · people with cerebral small vessel disease and no dementia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Stroke or transient ischaemic attack · people with cerebral small vessel disease and no dementia
1 finding from 1 review
Any adverse events (excluding major bleeding) · people with cerebral small vessel disease and no dementia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawal from study medication · people with cerebral small vessel disease and no dementia
1 finding from 1 review
All‐cause mortality · heart failure associated with central sleep apnoea
It is very uncertain whether PAP therapy changes all‐cause mortality compared with usual care (very low certainty).
1 finding from 1 review
Cardiac disease‐ related mortality · heart failure associated with central sleep apnoea
PAP therapy showed no clear difference in cardiac‐related mortality compared with usual care (moderate certainty).
1 finding from 1 review
Patient readmissions · heart failure associated with central sleep apnoea
PAP therapy showed no clear difference in all‐cause rehospitalisation compared with usual care (low certainty).
1 finding from 1 review
Cardiac‐related rehospitalisation · heart failure associated with central sleep apnoea
PAP therapy showed no clear difference in cardiac‐related rehospitalisation compared with usual care (low certainty).
1 finding from 1 review
QoL · heart failure associated with central sleep apnoea
2 findings from 1 review
Adverse events · heart failure associated with central sleep apnoea
1 finding from 1 review
Specific adverse events: serious haemorrhage · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serious haemorrhage compared with placebo plus chemotherapy (very low certainty).
1 finding from 1 review
Specific adverse events: serious thromboembolic events · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serious thromboembolic events compared with placebo plus chemotherapy (very low certainty).
1 finding from 1 review